Amgen’s AMGN stock has declined 12.1% in the past month. Late last month, Amgen announced the much-awaited 52-week top-line ...

Though the pharmaceutical giant isn't performing as well in the second half of the year as it did in the first, it still has ...

Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year of treatment, ...

The biotech industry can be volatile even for relatively large companies. Amgen ( AMGN 1.00%), one of the more prominent names in the game, just reminded us all of that fact. On Nov. 26, the company's ...

U.S. equities were mixed at midday following comments from President-elect Trump about new tariffs on Chinese, Canadian, and ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

The market didn't appreciate Amgen's (NASDAQ: AMGN) latest clinical data update, with the biopharma's shares falling more ...

Shares of Danish weight-loss drug maker Novo Nordisk rose 1.3% on Tuesday as U.S. President Joe Biden proposed expanding ...

Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even without the full upside from MariTide.

Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

Amgen reported that MariTide, a monthly or less frequent injectable, delivered up to 20% average weight loss at 52 weeks in ...